Mazyar Shadman

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.544Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis

British Journal of Haematology(2024)10.1111/bjh.19569

Top 36%

0.544DataRank

Top 36%12 citations

Hamza Hashmi, Kwang Woo Ahn, Mariam Allbee‐Johnson, Andy I. Chen, Baldeep Wirk +12 more

Papers

Driven by 43 papers — median percentile 64. Top paper: “γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial”.

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

The Lancet Oncology(2023)10.1016/s1470-2045(23)00246-2

N/A

2.5DataRank · unranked

101 citations

Margot J. Pont, Blythe Sather, Cameron J. Turtle, Brian G. Till, Edward N. Libby +15 more

Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2023011287

N/A

1.7DataRank · unranked

55 citations

Erik L. Kimble, Jocelyn H. Wright, Salvatore Fiorenza, Jordan Gauthier, Jenna Voutsinas +18 more

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

The Lancet Haematology(2021)10.1016/s2352-3026(21)00170-8

N/A

1.6DataRank · unranked

59 citations

Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren +15 more

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

Blood(2023)10.1182/blood.2022019254

N/A

1.4DataRank · unranked

39 citations

Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman +21 more

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

Blood Advances(2023)10.1182/bloodadvances.2023011399

N/A

0.958DataRank · unranked

34 citations

Aya Albittar, Jennifer J. Huang, Alexandre V. Hirayama, Erik L. Kimble, Andrew J. Portuguese +11 more

Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis

British Journal of Haematology(2024)10.1111/bjh.19569

Top 36%

0.544DataRank

Top 36%12 citations

Hamza Hashmi, Kwang Woo Ahn, Mariam Allbee‐Johnson, Andy I. Chen, Baldeep Wirk +12 more

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Blood Advances(2025)10.1182/bloodadvances.2024015314

N/A

0.447DataRank · unranked

10 citations

Emily C. Liang, Jennifer J. Huang, Erik L. Kimble, Alexandre V. Hirayama, Salvatore Fiorenza +15 more

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL

Blood Advances(2022)10.1182/bloodadvances.2022008628

N/A

0.240DataRank · unranked

3 citations

Ryan C. Lynch, Chaitra S. Ujjani, Ted Gooley, Heather Rasmussen, David G. Coffey +9 more

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma

Blood Advances(2025)10.1182/bloodadvances.2024014263

N/A

0.113DataRank · unranked

1 citations

Parastoo B. Dahi, Farhad Khimani, Andrei R. Shustov, Mazyar Shadman, Jia Ruan +19 more

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps7567

N/A

0DataRank · unranked

3 citations

Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch +9 more

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Blood(2022)10.1182/blood.2021014497

N/A

0DataRank · unranked

54 citations

Nicolas Gazeau, Alexandre V. Hirayama, Joshua A. Hill, Vicky Wu, Aisling Cearley +17 more

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Transplantation and Cellular Therapy(2023)10.1016/j.jtct.2023.04.001

N/A

0DataRank · unranked

140 citations

Emily C. Liang, Qian Wu, Jenna Voutsinas, Pere Barba, Gloria Iacoboni +19 more

CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007803

N/A

0DataRank · unranked

36 citations

Dong Hoon Lee, Wei Sun, Francisco Cervantes-Contreras, Ryan Basom, Feinan Wu +8 more

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Blood Advances(2023)10.1182/bloodadvances.2022009467

N/A

0DataRank · unranked

14 citations

Hongli Li, Diana G. Adlowitz, Janice M. Spence, Lisa M. Rimsza, Mazyar Shadman +7 more

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.10.002

N/A

0DataRank · unranked

12 citations

Ajay K. Gopal, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan +10 more

A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016

Hematological Oncology(2023)10.1002/hon.3163_79

N/A

0DataRank · unranked

2 citations

H. Li, Lisa M. Rimsza, John P. Leonard, Mark Kaminski, Catherine Spier +6 more

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7561

N/A

0DataRank · unranked

1 citations

Jonathan R. Fromm, Min Fang, Brian G. Till, Mazyar Shadman, Andrew J. Cowan +11 more

Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7511

N/A

0DataRank · unranked

1 citations

Alexandre V. Hirayama, Erik L. Kimble, Andrew J. Portuguese, Aya Albittar, Aude G. Chapuis +8 more

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Blood(2023)10.1182/blood-2023-173992

N/A

0DataRank · unranked

0 citations

Ted Gooley, Tanya Siddiqi, Deborah M. Stephens, Catherine M. Broome, Stephen E. Spurgeon +18 more

CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma

Blood Advances(2024)10.1182/bloodadvances.2024013863

N/A

0DataRank · unranked

21 citations

Joshua Fein, Kwang Woo Ahn, Molly Allbee-Johnson, Nausheen Ahmed, Farrukh T. Awan +14 more

Development and validation of predictive models of early immune effector cell–associated hematotoxicity

Blood Advances(2024)10.1182/bloodadvances.2024014455

N/A

0DataRank · unranked

10 citations

Jennifer J. Huang, Andrew J. Portuguese, Valentín Ortiz‐Maldonado, Aya Albittar, Natalie Wuliji +28 more

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Blood Advances(2024)10.1182/bloodadvances.2023011569

N/A

0DataRank · unranked

11 citations

Jenna Voutsinas, Bita Fakhri, Sirin Khajavian, Stephen E. Spurgeon, Deborah M. Stephens +30 more

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Leukemia & lymphoma/Leukemia and lymphoma(2024)10.1080/10428194.2024.2402814

N/A

0DataRank · unranked

8 citations

Monika Salkar, Bhavini Srivastava, Sudeep Karve, Bruno Émond, Priyanka Gogna +14 more

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Blood Neoplasia(2024)10.1016/j.bneo.2024.100047

N/A

0DataRank · unranked

6 citations

Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui +6 more

A phase 2 study of frontline pembrolizumab in follicular lymphoma

eJHaem(2024)10.1002/jha2.1029

N/A

0DataRank · unranked

0 citations

Songli Zhu, Ted Gooley, Taranjit S. Gujral, Ryan C. Lynch, Christina Poh +5 more

Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

UNC Libraries(2024)10.17615/d5s2-9s76

N/A

0DataRank · unranked

0 citations

Peter A. Riedell, R. Alejandro Sica, Tania Jain, Brian T. Hill, Craig S. Sauter +24 more

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL

Blood Cancer Journal(2025)10.1038/s41408-025-01236-6

N/A

0DataRank · unranked

12 citations

Ying Huang, Sarah Miller, John N. Allan, Seema A. Bhat, David A. Bond +40 more

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

Blood Advances(2025)10.1182/bloodadvances.2024015164

N/A

0DataRank · unranked

5 citations

Patrick W Flaherty, Hu Xie, Mandeep K Sekhon, Clementine Chalal, Terry Stevens‐Ayers +9 more

CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting

Transplantation and Cellular Therapy(2025)10.1016/j.jtct.2025.10.024

N/A

0DataRank · unranked

3 citations

Matthew A. Lunning, Mazyar Shadman, Sairah Ahmed, Jeremy S. Abramson, Miguel‐Angel Perales +14 more

Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS

British Journal of Haematology(2025)10.1111/bjh.70020

N/A

0DataRank · unranked

2 citations

Kwang Woo Ahn, Jinalben Patel, Qinghua Lian, Muhammad Bilal Abid, Ahmed Al Nughmush +18 more

Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial

Haematologica(2025)10.3324/haematol.2025.288057

N/A

0DataRank · unranked

1 citations

Hongli Li, Mazyar Shadman, Lisa M. Rimsza, Ahmad S. Zebari, Sonali M. Smith +5 more

143 | REAL‐WORLD OUTCOMES OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) FOR THE TREATMENT OF RICHTER TRANSFORMATION TO LARGE B‐CELL LYMPHOMA (RT‐LBCL)

Hematological Oncology(2025)10.1002/hon.70093_143

N/A

0DataRank · unranked

1 citations

Constance Lau, Mazyar Shadman, Alex F. Herrera, Caron A. Jacobson, F. L. Locke +13 more

Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory (R/R) secondary central nervous system lymphoma (SCNSL).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.7024

N/A

0DataRank · unranked

0 citations

Babatunde Adedokun, Hamza Hashmi, Mazyar Shadman, Allison Winter, Alex F. Herrera +14 more

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Blood(2020)10.1182/blood.2019002936

N/A

0DataRank · unranked

321 citations

Alexandre V. Hirayama, Janaki Purushe, Kevin A. Hay, James Lymp, Daniel H. Li +12 more

Influence of B cell or plasma cell-targeted CAR-T cell therapy on humoral immunity and vaccine immunogenicity: The HICAR study

Research Square(2025)10.21203/rs.3.rs-7061163/v1

N/A

0DataRank · unranked

0 citations

Stosh Ozog, Elizabeth M. Krantz, Karyn Tindbaek, Julián B. Muñoz, Winnie Liu +16 more

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Blood(2020)10.1182/blood.2020006965

N/A

0DataRank · unranked

318 citations

Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie, John M. Pagel +57 more

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3815

N/A

0DataRank · unranked

116 citations

Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander +49 more

BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1427

N/A

0DataRank · unranked

50 citations

Lindsey E. Roeker, Mazyar Shadman, Matthew S. Davids, Stephen J. Schuster, Anthony R. Mato +1 more

Management of CLL patients early in the COVID‐19 pandemic: An international survey of CLL experts

American Journal of Hematology(2020)10.1002/ajh.25851

N/A

0DataRank · unranked

21 citations

Anthony R. Mato, John C. Byrd, Alexey V. Danilov, Brad Hedrick, Chaitra S. Ujjani +6 more

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8038

N/A

0DataRank · unranked

1 citations

Jun Yin, Levi Pederson, Betsy LaPlant, Mazyar Shadman, Hongli Li +15 more

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Blood(2021)10.1182/blood.2021011841

N/A

0DataRank · unranked

70 citations

Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids +47 more

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.001

N/A

0DataRank · unranked

16 citations

Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling +29 more

CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7532

N/A

0DataRank · unranked

5 citations

Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Staci Williamson +10 more

Mazyar Shadman

Indexed papers

Top data-sharing exemplar

Papers